Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) Enterprise Value (2018 - 2025)

Historic Enterprise Value for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to -$648.3 million.

  • Bicycle Therapeutics' Enterprise Value rose 2722.5% to -$648.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$648.3 million, marking a year-over-year increase of 2722.5%. This contributed to the annual value of -$879.5 million for FY2024, which is 6707.48% down from last year.
  • Per Bicycle Therapeutics' latest filing, its Enterprise Value stood at -$648.3 million for Q3 2025, which was up 2722.5% from -$721.5 million recorded in Q2 2025.
  • Bicycle Therapeutics' 5-year Enterprise Value high stood at -$195.9 million for Q1 2021, and its period low was -$961.4 million during Q2 2024.
  • Over the past 5 years, Bicycle Therapeutics' median Enterprise Value value was -$438.7 million (recorded in 2021), while the average stood at -$508.3 million.
  • As far as peak fluctuations go, Bicycle Therapeutics' Enterprise Value tumbled by 22258.25% in 2021, and later soared by 2788.05% in 2023.
  • Quarter analysis of 5 years shows Bicycle Therapeutics' Enterprise Value stood at -$438.7 million in 2021, then grew by 22.69% to -$339.2 million in 2022, then tumbled by 55.22% to -$526.4 million in 2023, then tumbled by 67.07% to -$879.5 million in 2024, then rose by 26.29% to -$648.3 million in 2025.
  • Its Enterprise Value stands at -$648.3 million for Q3 2025, versus -$721.5 million for Q2 2025 and -$793.0 million for Q1 2025.